Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NICE update!
Status now "in progress" and decision "selected"!
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
It means she's ready to go. Upwards this time.
You should be updated to the FudsterBotV87.115.
They're more on the nerve of time.
DI said:
— My Shells (@My_Shells_) December 17, 2022
Call georgeson 800 932 9864. Open till 6 today. You can vote by phone.
This was for Canadian voters who reached out.
Did someone mention a while back that nwbo had wished for everyone to vote quickly, or something similar?
Not sure if I recall correctly.
But if so, where did nwbo say so?
I wouldn't do all that if I was still negotiating. Doing all that just on hopes of a deal coming through? No way.
The deal should already be inked before doing all that.
Prerequisite(s)?... Sawston?
The SEC says;
Fails-To-Deliver
The values of total fails-to-deliver shares represent the aggregate net balance of shares that failed to be delivered as of a particular settlement date. Fails to deliver on a given day are a cumulative number of all fails outstanding until that day, plus new fails that occur that day, less fails that settle that day. The figure is not a daily amount of fails, but a combined figure that includes both new fails on the reporting day as well as existing fails. In other words, these numbers reflect aggregate fails as of a specific point in time, and may have little or no relationship to yesterday's aggregate fails. Thus, it is important to note that the age of fails cannot be determined by looking at these numbers. If all shares were delivered on a particular day, then there will be no entry in the table.
If I understood that correctly it would mean that the total number of all FTDs as of 22/11/30 in NWBO was 5.6K.
This is the most ridiculous thing IMO.
They'll happily halt stocks every 10% gain if it's going up "To protect retail investors", but not when it goes down.
Seems about right. LOL.
Upload here;
https://imgbb.com/
And copy link to iHub
I'd guess it's this here;
I can guess why the presentation went private, and it might be good. Now back to the negotiating table, imo.
It's not that simple to compare the two trials, as I said in that post I linked to you, the DCVax+poly-iclc trial includes nGBM and rGBM, DCVax+Keytruda only rGBM which has worse outlook than nGBM.
We couldn't compare them unless we knew the median time to recurrence on DC+Poly and would have to exclude the possible WHO grade 3 glioma patients if there were any.
Someone with more knowledge can confirm if this is correct or if there's even more to it.
I think the answers to your questions are here;
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170623624
And regarding my question on that message, I think it is the same trial fromwhere LL shared the data.
It seems the fudsters might have reported the video... Tagged as private now.
https://support.google.com/youtube/answer/7300965?hl=en
1. The webinar hosted by @AlMusella yesterday answered this question; https://t.co/me6oapQJyc I set the video to start from where Dr. Liau addresses your concern. I suggest you watch the whole recording.
— Jack (@Pavacheese) December 6, 2022
2. The ITT population seems to have had that 17.4months OS.
You're welcome
Yes, we don't know that.
The Poly-ICLC trial contains both nGBM and rGBM and also seems to have allowed WHO grade 3 gliomas as well(?). The DCVax+Keytruda only rGBM.
I'm not sure if this data LL showed is from this trial (https://clinicaltrials.gov/ct2/show/NCT04201873) or not. As her slide says nothing about the poly-iclc but neither does this trialgov site under the sections "Study description" or "Official title".
But in the "Arms and interventions" poly-iclc is mentioned on both arms.
Hi, Beartrap,
The Poly-ICLC trial has been going for 12 years now: https://clinicaltrials.gov/ct2/show/NCT01204684
The slide we've seen showed 50% survival rate at 100 months. And I believe ATLinsider said he's seen a More recent one showing 50% at 120 months.
Also nwbo is not a sponsor nor a collaborator in the trial so I doubt it would be nwbo to issue any PRs regarding the trial.
Thank you so much, Beartrap!!
Thank you! I must've missed it. Have to re-watch.
Hi Beartrap,
Do you have a link or sth to somewhere where Linda has stated this? I would love to have that statement!
No, 1.3K yesterday morning. So they covered over 700k yesterday. Or people agreed to lend more shares.
Yesterday the shortable shares on IBKR was 1.3K, so they covered some.
Does someone in here have more knowledge regarding this dark pool volatility?
Seems quite "coincidental" that this kind of thing happens on the day we filed the suit.
This is a massive spike of DP volatility, with a huge switchover between DP and exchange trading.
— The Devil's Stock Broker (@TRUExDEMON) December 1, 2022
This is precisely what happened before $BBIG, $AMC, $SPRT, and $GME squeezed in the past. It's really hard to say anything for certain, but this is NOT normal behavior. https://t.co/hOZufLyH6h
If they had them already filed/ready to file, I don't think they'd disclose that for the first time in a lawsuit.
Would you say a falling wedge could maybe nudge it upwards?
Dr. Musella's tweet says Tuesday Nov 29th but it was postponed to Monday Dec 5th.
This one:
Our next webinar will be on DCVAX with very special guest speaker Dr. Linda Liau. Tuesday, Nov 29, 2022 at 7pm Eastern Time.
— Al Musella (@AlMusella) November 21, 2022
DC-Vax is an experimental vaccine therapy for Glioblastomas. https://t.co/ZSFrHyGNIl #dcvax #gbm
Historically NWBO has used the PRE14A only when they needed to raise the AS.
Only time will tell if that's the case this time, too.
Thanks! Awesome work!
Thanks Bio!
Spent a few hours last night trying to unveil all this and put it into a post but couldn't have presented the info nearly as well as you did!
I'd say that this terminated trial is a different one as there's no mention of the CSF-1 receptor inhibitor, only DCVax+Nivolumab.
Also that trial was terminated at latest on July 24, 2020.
LL's presentations including the BMS collaboration trial slides were held in 2021 and 2022.
Hey Bio,
Could it be that the Poly-ICLC used in this DCVax+Keytruda+Poly-ICLC combo trial ( https://clinicaltrials.gov/ct2/show/NCT04201873 ) actually is Hiltonol as under the 'Intervention/treatment' section it says;
Drug: Poly ICLC
Given IM
Other Names:
Hiltonol
Poly I:Poly C with Poly-L-Lysine Stabilizer
poly-ICLC
PolyI:PolyC with Poly-L-Lysine Stabilizer
Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose
Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose
Stabilized Polyriboinosinic/Polyribocytidylic Acid
Maybe not any significance in that even if it really is Hiltonol. But anyways I found it even somewhat interesting bit
Yes that one exactly.
I do think it is possible that UCLA is collaborating with both BMS (BMY) & Merck (MRK).
Mr. Bigger seems to expect data on the Keytruda trial at the beginning of next year:
T+3 years not days. T early 2020
— Michael Bigger (@biggercapital) November 27, 2022
Yes she does say that this new SPORE project is with BMS.
Also I thought I had seen these same slides somewhere and, yes it was in this video where LL also presents the Poly-ICLC combo survival data;
Didn't have time to watch it yet. Though I think I've seen it already but can't remember much of it haha. Will have it a go in a bit.
Should always write everything down as there's just too much info around to remember...
There are actually two different sites to read about the SPORE projects. On the other one they specifically mention Merck and Pembrolizumab (Keytruda), on the other one they do not.
This one has the mention:
https://trp.cancer.gov/spores/abstracts/ucla_brain.htm
This one does not:
https://cancer.ucla.edu/research/ucla-brain-spore/research-projects